Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

COVID-19 Diagnostics Market Research Report Information by Type (Molecular Tests, Serology Tests), Technology (RT-PCR, Isothermal Amplification, CRISPR, ELISA, Hybridization), End-User (Hospitals, Public Health Labs, Private or Commercial Labs), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2030


ID: MRFR/HC/8232-CR | 119 Pages | Author: Rahul Gotadki| February 2021

Research Methodology on Covid-19 Diagnostics Market


Objective of the Study:


The primary objective of the proposed study is to analyze the market potential of Covid-19 diagnostics and strategies adopted by industry participants to capitalize on the same. Additionally, the study also aims to evaluate the overall awareness, demand, and future market opportunities of Covid-19 diagnostics.


Research Design:


The research design adopted for this proposed research study is both qualitative and quantitative. Qualitative research methods are employed for understanding the behaviour and preferences of the target audience and to assess the overall awareness about Covid-19 diagnostics. On the other hand, quantitative research is undertaken to analyse the current market conditions, major industry players and the strategies adopted by them. The various sources from which the data is obtained include published reports, testimonials, web resources, interviews with industry experts/operators, surveys, and other secondary sources of data.


Data Collection Process:


Primary Data Collection


The primary data for the study is mainly collected from surveys, questionnaires and interviews with the participants of the market like market players, and the end-users of the Covid-19 diagnostics. The primary data collection process is aimed at gaining permission to conduct surveys, reaching out to a sample set of customers and preparing questionnaires and opinion polls that could result in meaningful insights into the Covid-19 diagnostics market. The sample size in this study is obtained from individuals sourced by randomly selected populations and personal contacts.


Secondary Data Sources


The secondary data sources used in the research report include published reports, web resources, testimonials, surveys and other sources. The data provided on the website of the various market participants as well as various other research databases and other third-party sources are used for assessing the trend of the Covid-19 diagnostics market. The sources are mostly authentic, reliable, and credible.


Data Analysis


In the reporting phase of the research study, the data collected from primary and secondary sources are analyzed by employing the methods of quantitative and qualitative data analysis. Since the research is mainly concerned with understanding the market size, Porter's Five Forces Model is employed for analyzing the various factors that govern the market. The market is further analyzed by evaluating the trend of the major players in the market with the help of secondary data sources.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

1 EXECUTIVE SUMMARY

1.1 OVERVIEW 14

1.2 MARKET SYNOPSIS 14

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

3 RESEARCH METHODOLOGY

3.1 OVERVIEW 16

3.2 DATA MINING 16

3.3 SECONDARY RESEARCH 16

3.4 PRIMARY RESEARCH 18

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING METHODS 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 21

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 22

3.8 VALIDATION 22

3.9 ASSUMPTIONS AND LIMITATIONS 23

3.9.1 ASSUMPTIONS AND LIMITATIONS 23

3.9.2 MARKET FACTORS 23

4 MARKET DYNAMICS

4.1 OVERVIEW 25

4.2 DRIVERS 26

4.2.1 INCREASING NUMBER OF COVID-19 CASES 26

4.2.2 GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26

4.2.3 RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26

4.2.4 DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27

4.3 RESTRAINTS 28

4.3.1 RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28

4.3.2 ACCURACY OF TEST RESULTS 28

4.4 OPPORTUNITIES 28

4.4.1 DEVELOPMENT OF QUICK, ACCURATE, AND AFFORDABLE TESTS 28

4.4.2 COLLABORATION OF MAJOR PLAYERS WITH SMALL PLAYERS 28

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 29

5.1.1 THREAT OF NEW ENTRANTS 29

5.1.2 BARGAINING POWER OF SUPPLIERS 30

5.1.3 THREAT OF SUBSTITUTES 30

5.1.4 BARGAINING POWER OF BUYERS 30

5.1.5 INTENSITY OF RIVALRY 30

5.2 SUPPLY CHAIN ANALYSIS 31

5.2.1 R&D AND DESIGNING 32

5.2.2 MANUFACTURING 32

5.2.3 DISTRIBUTION 32

5.2.4 MARKETING & SALES 32

5.2.5 POST-SALES MONITORING 32

5.3 IMPACT OF COVID-19 ON SUPPLY OF DIAGNOSTIC DEVICES 32

6 COVID-19 DIAGNOSTICS MARKET, BY TYPE

6.1 OVERVIEW 33

6.2 MOLECULAR TESTS 34

6.3 SEROLOGY TESTS 36

7 COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

7.1 OVERVIEW 38

7.2 RT-PCR 40

7.3 ISOTHERMAL AMPLIFICATION 40

7.4 CRISPR 41

7.5 ELISA 42

7.6 HYBRIDIZATION 43

7.7 OTHERS 43

8 COVID-19 DIAGNOSTICS MARKET, BY END USER

8.1 OVERVIEW 44

8.2 HOSPITALS 45

8.3 PUBLIC HEALTH LABS 46

8.4 PRIVATE OR COMMERCIAL LABS 47

9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION

9.1 OVERVIEW 48

9.2 EUROPE 50

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1 WESTERN EUROPE 52

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.1 GERMANY 53

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.2 SPAIN 54

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.3 ITALY 55

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.4 UK 56

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.5 FRANCE 57

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.6 REST OF WESTERN EUROPE 58

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.2 EASTERN EUROPE 59

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3 AMERICAS 61

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.1 NORTH AMERICA 63

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.1.1 US 64

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.1.2 CANADA 65

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.2 LATIN AMERICA 66

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4 ASIA-PACIFIC 68

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.1 INDIA 70

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.2 AUSTRALIA 71

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.3 SOUTH KOREA 72

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.4 JAPAN 73

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.5 CHINA 74

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.6 REST OF ASIA-PACIFIC 75

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.5 MIDDLE EAST & AFRICA 77

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.5.1 MIDDLE EAST 79

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.5.2 AFRICA 80

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW 81

10.2 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81

10.3 GLOBAL COVID-19 DIAGNOSTICS MARKET INSIGHTS 82

10.4 COMPETITIVE BENCHMARKING 83

10.5 COMPETITOR DASHBOARD 84

10.6 MAJOR GROWTH STRATEGIES IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85

10.7 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86

10.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 86

10.8.1 PRODUCT LAUNCHES 87

10.8.2 ACQUISITIONS 88

10.8.3 CONTRACTS 88

11 COMPANY PROFILES

11.1 BECTON, DICKINSON AND COMPANY 89

11.1.1 COMPANY OVERVIEW 89

11.1.2 FINANCIAL OVERVIEW 90

11.1.3 PRODUCTS/SERVICES OFFERED 90

11.1.4 KEY DEVELOPMENTS 91

11.1.5 SWOT ANALYSIS 91

11.1.6 KEY STRATEGIES 91

11.2 BIO-RAD LABORATORIES, INC. 92

11.2.1 COMPANY OVERVIEW 92

11.2.2 FINANCIAL OVERVIEW 92

11.2.3 PRODUCTS/SERVICES OFFERED 93

11.2.4 KEY DEVELOPMENTS 93

11.2.5 SWOT ANALYSIS 94

11.2.6 KEY STRATEGIES 94

11.3 DANAHER CORPORATION 95

11.3.1 COMPANY OVERVIEW 95

11.3.2 FINANCIAL OVERVIEW 96

11.3.3 PRODUCTS/SERVICES OFFERED 96

11.3.4 KEY DEVELOPMENTS 97

11.3.5 SWOT ANALYSIS 97

11.3.6 KEY STRATEGIES 97

11.4 ABBOTT 98

11.4.1 COMPANY OVERVIEW 98

11.4.2 FINANCIAL OVERVIEW 99

11.4.3 PRODUCTS/SERVICES OFFERED 99

11.4.4 KEY DEVELOPMENTS 100

11.4.5 SWOT ANALYSIS 100

11.4.6 KEY STRATEGIES 100

11.5 F. HOFFMANN-LA ROCHE LTD 101

11.5.1 COMPANY OVERVIEW 101

11.5.2 FINANCIAL OVERVIEW 102

11.5.3 PRODUCTS/SERVICES OFFERED 102

11.5.4 KEY DEVELOPMENTS 103

11.5.5 SWOT ANALYSIS 103

11.5.6 KEY STRATEGIES 103

11.6 BIOMÉRIEUX SA 104

11.6.1 COMPANY OVERVIEW 104

11.6.2 FINANCIAL OVERVIEW 104

11.6.3 PRODUCTS/SERVICES OFFERED 105

11.6.4 PRODUCTS/SERVICES PIPELINE 105

11.6.5 KEY DEVELOPMENTS 105

11.6.6 SWOT ANALYSIS 106

11.6.7 KEY STRATEGIES 106

11.7 GENMARK DIAGNOSTICS, INC. 107

11.7.1 COMPANY OVERVIEW 107

11.7.2 FINANCIAL OVERVIEW 107

11.7.3 PRODUCTS/SERVICES OFFERED 108

11.7.4 KEY DEVELOPMENTS 108

11.7.5 SWOT ANALYSIS 108

11.7.6 KEY STRATEGIES 108

11.8 THERMO FISHER SCIENTIFIC INC. 109

11.8.1 COMPANY OVERVIEW 109

11.8.2 FINANCIAL OVERVIEW 109

11.8.3 PRODUCTS/SERVICES OFFERED 110

11.8.4 KEY DEVELOPMENTS 110

11.8.5 SWOT ANALYSIS 110

11.8.6 KEY STRATEGIES 111

11.9 QIAGEN 112

11.9.1 COMPANY OVERVIEW 112

11.9.2 FINANCIAL OVERVIEW 113

11.9.3 PRODUCTS/SERVICES OFFERED 113

11.9.4 KEY DEVELOPMENTS 114

11.9.5 SWOT ANALYSIS 114

11.9.6 KEY STRATEGIES 114

11.10 SIEMENS AG 115

11.10.1 COMPANY OVERVIEW 115

11.10.2 FINANCIAL OVERVIEW 115

11.10.3 PRODUCTS/SERVICES OFFERED 116

11.10.4 KEY DEVELOPMENTS 116

11.10.5 SWOT ANALYSIS 116

11.10.6 KEY STRATEGIES 117

12 APPENDIX

12.1 REFERENCES 118

12.2 RELATED REPORTS 119

13 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS AND LIMITATIONS 23

TABLE 2 NUMBER OF NEW CASES IN COUNTRIES THAT ARE MOST AFFECTED BY COVID-19 AS OF 18 MAY 2022 26

TABLE 3 DEVELOPMENTS BY PHARMACEUTICAL COMPANIES TO BOOST THE TESTING OF COVID-19 27

TABLE 4 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 34

TABLE 5 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 MOLECULAR TESTS DURING THE PUBLIC HEALTH EMERGENCY 35

TABLE 6 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR MOLECULAR TESTS, BY REGION, 2022-2030 (USD MILLION) 35

TABLE 7 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 SEROLOGICAL TESTS DURING THE PUBLIC HEALTH EMERGENCY 36

TABLE 8 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR SEROLOGY TESTS, BY REGION, 2022-2030 (USD MILLION) 37

TABLE 9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 39

TABLE 10 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR RT-PCR, BY REGION, 2022-2030 (USD MILLION) 40

TABLE 11 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 DURING THE PUBLIC HEALTH EMERGENCY: USING ISOTHERMAL AMPLIFICATION TECHNOLOGY 41

TABLE 12 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR ISOTHERMAL AMPLIFICATION, BY REGION, 2022-2030 (USD MILLION) 41

TABLE 13 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR CRISPR, BY REGION, 2022-2030 (USD MILLION) 42

TABLE 14 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 DURING THE PUBLIC HEALTH EMERGENCY: USING ELISA 42

TABLE 15 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR ELISA, BY REGION, 2022-2030 (USD MILLION) 43

TABLE 16 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR HYBRIDIZATION, BY REGION, 2022-2030 (USD MILLION) 43

TABLE 17 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 45

TABLE 18 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2022-2030 (USD MILLION) 46

TABLE 19 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR PUBLIC HEALTH LABS, BY REGION, 2022-2030 (USD MILLION) 46

TABLE 20 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR PRIVATE OR COMMERCIAL LABS, BY REGION, 2022-2030 (USD MILLION) 47

TABLE 21 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 49

TABLE 22 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 50

TABLE 23 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 51

TABLE 24 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 51

TABLE 25 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 51

TABLE 26 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 52

TABLE 27 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 52

TABLE 28 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 53

TABLE 29 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 53

TABLE 30 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 53

TABLE 31 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 54

TABLE 32 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 54

TABLE 33 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 54

TABLE 34 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 55

TABLE 35 ITALY: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 55

TABLE 36 ITALY: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 55

TABLE 37 ITALY: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 56

TABLE 38 UK: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 56

TABLE 39 UK: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 56

TABLE 40 UK: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 57

TABLE 41 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 57

TABLE 42 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 57

TABLE 43 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 58

TABLE 44 REST OF WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 58

TABLE 45 REST OF WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 58

TABLE 46 REST OF WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 59

TABLE 47 EASTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 59

TABLE 48 EASTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 59

TABLE 49 EASTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 60

TABLE 50 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 61

TABLE 51 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 62

TABLE 52 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 62

TABLE 53 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 62

TABLE 54 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 63

TABLE 55 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 63

TABLE 56 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 64

TABLE 57 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 64

TABLE 58 US: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 64

TABLE 59 US: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 65

TABLE 60 US: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 65

TABLE 61 CANADA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 65

TABLE 62 CANADA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 66

TABLE 63 CANADA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 66

TABLE 64 LATIN AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 66

TABLE 65 LATIN AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 67

TABLE 66 LATIN AMERICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 67

TABLE 67 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 69

TABLE 68 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 69

TABLE 69 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 69

TABLE 70 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 70

TABLE 71 INDIA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 70

TABLE 72 INDIA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 70

TABLE 73 INDIA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 71

TABLE 74 AUSTRALIA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 71

TABLE 75 AUSTRALIA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 71

TABLE 76 AUSTRALIA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 72

TABLE 77 SOUTH KOREA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 72

TABLE 78 SOUTH KOREA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 72

TABLE 79 SOUTH KOREA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 73

TABLE 80 JAPAN: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 73

TABLE 81 JAPAN: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 73

TABLE 82 JAPAN: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 74

TABLE 83 CHINA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 74

TABLE 84 CHINA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 74

TABLE 85 CHINA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 75

TABLE 86 REST OF ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 75

TABLE 87 REST OF ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 75

TABLE 88 REST OF ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 76

TABLE 89 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 77

TABLE 90 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 78

TABLE 91 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 78

TABLE 92 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 78

TABLE 93 MIDDLE EAST: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 79

TABLE 94 MIDDLE EAST: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 79

TABLE 95 MIDDLE EAST: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 79

TABLE 96 AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 80

TABLE 97 AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 80

TABLE 98 AFRICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 80

TABLE 99 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81

TABLE 100 COMPETITOR DASHBOARD: GLOBAL COVID-19 DIAGNOSTICS MARKET 84

TABLE 101 THE MOST ACTIVE PLAYER IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86

TABLE 102 PRODUCT LAUNCHES 87

TABLE 103 ACQUISITIONS 88

TABLE 104 CONTRACTS 88

TABLE 105 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED 90

TABLE 106 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS 91

TABLE 107 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 93

TABLE 108 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS 93

TABLE 109 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 96

TABLE 110 DANAHER CORPORATION: KEY DEVELOPMENTS 97

TABLE 111 ABBOTT: PRODUCTS/SERVICES OFFERED 99

TABLE 112 ABBOTT: KEY DEVELOPMENTS 100

TABLE 113 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 102

TABLE 114 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 103

TABLE 115 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 105

TABLE 116 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 105

TABLE 117 BIOMÉRIEUX SA: KEY DEVELOPMENTS 105

TABLE 118 GENMARK DIAGNOSTICS, INC.: PRODUCTS/SERVICES OFFERED 108

TABLE 119 GENMARK DIAGNOSTICS, INC.: KEY DEVELOPMENTS 108

TABLE 120 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 110

TABLE 121 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 110

TABLE 122 QIAGEN: PRODUCTS/SERVICES OFFERED 113

TABLE 123 QIAGEN: KEY DEVELOPMENTS 114

TABLE 124 SIEMENS AG: PRODUCTS/SERVICES OFFERED 116

TABLE 125 SIEMENS AG: KEY DEVELOPMENTS 116

14 LIST OF FIGURES

FIGURE 1 GLOBAL COVID-19 DIAGNOSTICS MARKET STRUCTURE 15

FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 21

FIGURE 3 MARKET DYNAMICS: GLOBAL COVID-19 DIAGNOSTICS MARKET 25

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL COVID-19 DIAGNOSTICS MARKET 29

FIGURE 5 SUPPLY CHAIN ANALYSIS: GLOBAL COVID-19 DIAGNOSTICS MARKET 31

FIGURE 6 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022 (%) 33

FIGURE 7 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2021 & 2030 (USD MILLION) 34

FIGURE 8 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 (%) 38

FIGURE 9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 & 2030 (USD MILLION) 39

FIGURE 10 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 (%) 44

FIGURE 11 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 & 2030 (USD MILLION) 45

FIGURE 12 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 48

FIGURE 13 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION, 2021 & 2030 (USD MILLION) 48

FIGURE 14 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 50

FIGURE 15 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (%) 52

FIGURE 16 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 61

FIGURE 17 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (%) 63

FIGURE 18 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (%) 68

FIGURE 19 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 77

FIGURE 20 BENCHMARKING OF MAJOR COMPETITORS 83

FIGURE 21 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85

FIGURE 22 GLOBAL COVID-19 DIAGNOSTICS MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 86

FIGURE 23 BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 90

FIGURE 24 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS 91

FIGURE 25 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 92

FIGURE 26 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 94

FIGURE 27 DANAHER CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 96

FIGURE 28 DANAHER CORPORATION: SWOT ANALYSIS 97

FIGURE 29 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 99

FIGURE 30 ABBOTT: SWOT ANALYSIS 100

FIGURE 31 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 102

FIGURE 32 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 103

FIGURE 33 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT 104

FIGURE 34 BIOMÉRIEUX SA: SWOT ANALYSIS 106

FIGURE 35 GENMARK DIAGNOSTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT 107

FIGURE 36 GENMARK DIAGNOSTICS, INC.: SWOT ANALYSIS 108

FIGURE 37 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 109

FIGURE 38 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 110

FIGURE 39 QIAGEN: FINANCIAL OVERVIEW 113

FIGURE 40 QIAGEN: SWOT ANALYSIS 114

FIGURE 41 SIEMENS AG: FINANCIAL OVERVIEW SNAPSHOT 115

FIGURE 42 SIEMENS AG: SWOT ANALYSIS 116

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.